Sphingomonas paucimobilis bacteremia from multiple clinical samples in a nosocomial infection in Erbil City
Abstract
Abstract
Background: Sphingomonas paucimobilis is a gram-negative pathogen that causes urinary tract infections, diarrhea, septicemia, and wound infections. Due to the spread of patients with high mortality but low mortality in Sphingomonas paucimobilis, it has been isolated from different clinical samples and is increasing antibiotic resistance all over the world.
Objectives: The aim of our research was to look at the epidemiology, antibiotic susceptibility series, and pathogenic potential of clinical samples from Erbil's Rizgary and Raparin hospitals.
Materials and Methods: A total of 2582 samples were reviewed from different clinical samples from Rizgary Hospital and Raparin Hospital from male and female, we found 24 Sphingomonas paucimobilis isolates, identified by using microscopical, morphological, biochemical tests and Vitek2 compact system according to the standard protocol against Ampicillin/Sulbactam, Cefazolin, Ceftazidime, Ceftriaxone, Cefepime, Imipenem, Tobramycin, Ciprofloxacin, Lev- ofloxacin, Trimethoprim. using Vitek 2 compact system.
Results: 24 total positive results of Sphingomonas paucimobilis isolated from 2582 different clinical specimens the highest percentage of Sphingomonas paucimobilis was isolated from female samples (65%) while from male (35%) wen performing antibiotic susceptibility the highest resistance rate was Trimethoprim (66.66%), followed by To bramycin (50%), Ciprofloxacin (50%) and Levofloxacin (41.66%), respectively in contrast the highest effective antibiotic against Sphingomonas paucimobilis was Cefepime (75%), Imipenem (75%), followed by Ceftriaxone (66.66%), Ceftazidime (66.66%), Cefazolin (66.66%), Ampicillin/Sulbactam (66.66%) Conclusion: Morbidity attribute to antibiotic resistance to third generation cephalosporin resistant, Sphingomonas paucimobilis resistant is significant, if prevailing resistance trends continue, high societal and economic costs can be expected. Better management of antibiotic use, and infection control is needed to avoid infections that caused by drug resistant pathogens like Sphingomonas paucimobilis.
Downloads
References
E. T. Rietschel, H.-D. Flad, and A. J. Ulmer, “Glycosphingolipids from sph- ingomonas paucimobilis induce monokine production in human mononu- clear cells.” Infection and immunity, vol. 63, no. 8, pp. 2899–2905, 1995.
[2] M. Peel, J. Davis, W. Armstrong, J. Wilson, and B. Holmes, “Pseudomonas paucimobilis from a leg ulcer on a japanese seaman.” Journal of clinical microbiology, vol. 9, no. 5, pp. 561–564, 1979.
[3] E. Yabuuchi, I. Yano, H. Oyaizu, Y. Hashimoto, T. Ezaki, and H. Ya- mamoto, “Proposals of sphingomonas paucimobilis gen. nov. and comb. nov., sphingomonas parapaucimobilis sp. nov., sphingomonas yanoikuyae sp. nov., sphingomonas adhaesiva sp. nov., sphingomonas capsulata comb, nov., and two genospecies of the genus sphingomonas,” Microbiology and immunology, vol. 34, no. 2, pp. 99–119, 1990.
[4] E. Angelakis, V. Roux, and D. Raoult, “Sphingomonas mucosissima bac- teremia in patient with sickle cell disease,” Emerging infectious diseases, vol. 15, no. 1, p. 133, 2009.
[5] N. R. Krieg and H. Manual, “Systematic bacteriology,” Williams Baltimore, 1984.
[6] K. Kawahara, M. Matsuura, and H. Danbara, “Chemical structure and bi- ological activity of lipooligosaccharide isolated from sphingomonas pauci- mobilis, a gram-negative bacterium lacking usual lipopolysaccharide,” Japanese journal of medical science & biology, vol. 43, no. 6, p. 250, 1990.
[7] P. M Tille, “Bailey & scott’s diagnostic microbiology fourteenth edition,” 2017.
[8] J. Reina, A. Bassa, I. Llompart, D. Portela, and N. Borrell, “Infections with pseudomonas paucimobilis: report of four cases and review,” Reviews of infectious diseases, vol. 13, no. 6, pp. 1072–1076, 1991.
[9] A. Kilic, Z. Senses, A. E. Kurekci, H. Aydogan, K. Sener, E. Kismet, and
A. C. Basustaoglu, “Nosocomial outbreak of sphingomonas paucimobilis bacteremia in a hemato/oncology unit,” Japanese journal of infectious dis- eases, vol. 60, no. 6, p. 394, 2007.
[10] M.-S. Yim, Y. C. Yau, A. Matlow, J.-S. So, J. Zou, C. A. Flemming,
H. Schraft, and K. T. Leung, “A novel selective growth medium-pcr assay to isolate and detect sphingomonas in environmental samples,” Journal of microbiological methods, vol. 82, no. 1, pp. 19–27, 2010.
[11] X. Zeng and J. Lin, “Beta-lactamase induction and cell wall metabolism in gram-negative bacteria,” Frontiers in microbiology, vol. 4, p. 128, 2013.
[12] M. O¨ zdemir, S. Pekcan, M. E. Demircili, F. E. Ta¸sbent, B. Feyzio˘glu, S¸. Pirin¸c, and M. Baykan, “A rare cause of bacteremia in a pediatric patient with down syndrome: Sphingomonas paucimobilis,” International journal of medical sciences, vol. 8, no. 7, p. 537, 2011.
[13] M. S. Wilke, A. L. Lovering, and N. C. Strynadka, “β-lactam antibiotic resistance: a current structural perspective,” Current opinion in microbi- ology, vol. 8, no. 5, pp. 525–533, 2005.
[14] I.-C. Kuo, P.-L. Lu, W.-R. Lin, C.-Y. Lin, Y.-W. Chang, T.-C. Chen, and Y.-H. Chen, “Sphingomonas paucimobilis bacteraemia and septic arthritis in a diabetic patient presenting with septic pulmonary emboli,” Journal of medical microbiology, vol. 58, no. 9, pp. 1259–1263, 2009.
[15] U. Eigner, A. Schmid, U. Wild, D. Bertsch, and A.-M. Fahr, “Analysis of the comparative workflow and performance characteristics of the vitek 2 and phoenix systems,” Journal of clinical microbiology, vol. 43, no. 8, pp. 3829–3834, 2005.
[16] O. Perola, T. Nousiainen, S. Suomalainen, S. Aukee, U.-M. K¨arkk¨ainen,
J. Kauppinen, T. Ojanen, and M.-L. Katila, “Recurrent sphingomonas paucimobilis-bacteraemia associated with a multi-bacterial water-borne epidemic among neutropenic patients,” Journal of Hospital Infection, vol. 50, no. 3, pp. 196–201, 2002.
[17] S. H. Bakir and F. A. Ali, “Evalution of multi-drug resistance and esbl, ampc, metallo β-lactamase production in gram negative bacteria causing pharyngotonsillitis,” International Journal of Research, vol. 8, 2015.
[18] S. S. Ahmad and F. A. Ali, “Detection of esbl, ampc and metallo beta- lactamase mediated resistance in gram-negative bacteria isolated from women with genital tract infection,” European Scientific Journal, vol. 10, no. 9, 2014.
[19] M. Ryan and C. Adley, “Sphingomonas paucimobilis: a persistent gram- negative nosocomial infectious organism,” Journal of Hospital Infection, vol. 75, no. 3, pp. 153–157, 2010.
[20] H.-S. Toh, H.-T. Tay, W.-K. Kuar, T.-C. Weng, H.-J. Tang, and C.-K. Tan, “Risk factors associated with sphingomonas paucimobilis infection,” Journal of Microbiology, Immunology and Infection, vol. 44, no. 4, pp. 289– 295, 2011.
[21] P.-R. Hsueh, L.-J. Teng, P.-C. Yang, Y.-C. Chen, H.-J. Pan, S.-W. Ho, and K.-T. Luh, “Nosocomial infections caused by sphingomonas paucimo- bilis: clinical features and microbiological characteristics,” Clinical Infec- tious Diseases, vol. 26, no. 3, pp. 676–681, 1998.
[22] J. G. Paez, A. S. Levin, M. Basso, L. B. Gomez, S. Gobara, F. Spad˜ao,
I. Oshiro, and S. F. Costa, “Trends in stenotrophomonas maltophilia blood- stream infection in relation to usage density of cephalosporins and car- bapenems during 7 years,” Infection Control & Hospital Epidemiology, vol. 29, no. 10, pp. 989–990, 2008.
[23] H. A. Hamadamin, S. T. Baban, B. M. Hussen, and F. A. Ali, “Distribution of blatem gene among escherichia coli strains isolated from different clinical samples in erbil city,” Journal of Kirkuk Medical College Vol, vol. 7, no. 1, 2019.
[24] F. A. Ali, B. M. Hussen, and S. M. Zaki, “Molecular detection of bla ctx-m gene among pseudomonas aeruginosa strains isolated from different clinical samples in erbil city,” Annals of Tropical Medicine and Health, vol. 23, pp. 231–231,
Copyright © Author(s) . This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
